Value of Time and Money
Applied Clinical Trials
Industry Standard Research has recently released its 3rd annual "CRO Quality Benchmarking Report." The report not only profiles the delivery quality of leading CROs, but also provides a wealth of information that relates to larger industry trends, including the value of recruitment speed.
Industry Standard Research has recently released its 3rd annual "CRO Quality Benchmarking Report." The report not only profiles the delivery quality of leading CROs, but also provides a wealth of information that relates to larger industry trends, including the value of recruitment speed.
After three consecutive years of collecting data, a critical mass to reflect upon has been collected. The basic statistics class axiom: "It takes three data points to make a trend," has been met.
Source: ISR Reports: Survey participants were asked to indicate their preference for one benefit over the other. n=160 (2009); 150 (2010); 169 (2011)
After examining the data, it is clear and undeniable: sponsors are expressing an unmet need for faster recruitment. It's not difficult to make sense of this. Project manager job appraisals and compensation are tied to trial speed. In addition, the rule-of-thumb is that for each day's delay in getting a drug to market, the manufacturer loses a million dollars in revenue. Perhaps to some readers this qualifies as a "duh" take-away, but the magnitude of the disparity remains interesting—price is important too.
Patient recruitment continues to be a source of consternation in the industry, and service providers are constantly measured against this metric. The ones that do it well will establish loyalty among their customers and the ones that do it poorly will struggle.
—Industry Standard Research, www.ISRreports.com.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
